Condition: Recurrent Pericarditis · Heart Diseases · Pericarditis · Sponsor: Kiniksa Pharmaceuticals International, plc
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
This description comes directly from the study's public registry record.
Clinical Project Manager · 781-431-9100 · clinicaltrials@kiniksa.com
Always discuss trial participation with your own doctor first.
| Investigational Site 031 | Phoenix, Arizona, United States | Recruiting |
| Investigational Site 014 | Los Angeles, California, United States | Recruiting |
| Investigational Site 002 | Santa Monica, California, United States | Recruiting |
| Investigational Site 039 | Jacksonville, Florida, United States | Recruiting |
| Investigational Site 013 | Chicago, Illinois, United States | Recruiting |
| Investigational Site 025 | Baltimore, Maryland, United States | Recruiting |
| Investigational Site 028 | Rochester, Minnesota, United States | Recruiting |
| Investigational Site 011 | New York, New York, United States | Recruiting |
| Investigational Site 003 | New York, New York, United States | Recruiting |
| Investigational Site 009 | Cincinnati, Ohio, United States | Recruiting |
| Investigational Site 005 | Austin, Texas, United States | Recruiting |
| Investigational Site 006 | Houston, Texas, United States | Recruiting |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07288216